Companies are limited in the opportunities to in-licensing more clinical and commercially viable assets due to commercial capacity and capability constraints.
However, by not exploring in-licensing opportunities, large pharma is missing out on opportunities for meaningful growth.
Ready to learn how you can overcome these in-licensing challenges? Schedule a time to meet with our in-licensing experts to learn more.